Free Newsletter
Pharma mulls $100M reform-ad campaign
You've heard that drugmakers have funded a new Harry-and-Louise ad campaign for healthcare reform. You may have even seen some of the commercials. Well, get ready for lots more pharma-backed advertising--because the industry is considering ploughing $100 million or more into a campaign beginning as early as September, sources told Bloomberg.
The current plan is to run television commercials in August in states where drugmakers maintain operations, depicting pharma as a linchpin of local economies, PhRMA SVP Ken Johnson told the news service. Then in September, PhRMA may back a huge healthcare reform push, with ads aimed at supporting reform efforts the industry can believe in.
We already know what the industry doesn't believe in: government price negotiation, even for Medicare drugs. That's one reason why pharma was so quick to step up with promises of cost cuts. That $80 billion pledge was designed to forestall provisions drugmakers don't like, such as price negotiation and drug reimportation from lower-cost markets such as Canada. Now, of course, that agreement looks rather limited, because a) the House doesn't recognize it, because it was settled with Sen. Max Baucus; and b) some Democratic Senators are saying pharma price cuts shouldn't be off the table. No wonder drugmakers want to take their case to the public.
- read the Bloomberg piece
Related Articles:
Next up in reform debate: Medicare rebates
PhRMA backs new Harry-and-Louise ads
House bill includes $50B drug-price rebates
Drugmakers pledge $80B to health reform
Pharma offense is best reform defense
Read pharma's lips: No public plan
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: